All Oncology News

Colton Jones, MD, and Joel Saltzman, MD, discuss the potential role of GLP-1 receptor agonists in CRC prevention based on retrospective data.

A Mayo Clinic study helped clarify how immune-related kidney inflammation develops and provided preclinical evidence on a targeted approach to mitigate these adverse effects.

Tafasitamab in combination with rituximab and lenalidomide has been approved for relapsed or refractory follicular lymphoma in Australia.

Amivantamab plus lazertinib improves second-line PFS vs osimertinib in EGFR-mutant NSCLC, per post hoc data from MARIPOSA presented at AACR 2026.

Early evidence suggests a dual bispecific strategy may be able to move the needle forward for patients with platinum-resistant ovarian cancer or endometrial cancer.

The brain-penetrant, noncovalent EGFR TKI produced an ORR of 87.5% in 8 efficacy-evaluable patients with EGFR-mutant NSCLC.

The fourth-generation EGFR C797S inhibitor ABK-EGFR-1 showed promising in vivo efficacy in various EGFR C797S mutation models.

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

A new UCLA study suggests the organization of immune cells inside melanoma tumors may help show which patients benefit from combination immunotherapy

The FDA has extended the target action date to review a BLA seeking the approval of subcutaneous isatuximab for multiple myeloma.

A response to neoadjuvant chemotherapy was associated with long-term survival benefits in high-risk UTUC.

Sac-TMT produced durable responses with a manageable safety profile in pretreated advanced/metastatic urothelial carcinoma.

Post-treatment ctDNA positivity was associated with disease recurrence in locoregionally advanced HNSCC, including p16-positive oropharynx cancer.

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

Toni Choueiri, MD, of Dana-Farber Cancer Institute, was elected to The Association of American Physicians.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

Maurie Markman, MD, highlights the frequently complex arena of goals of care discussions in oncology.

China’s NMPA approved belantamab mafodotin plus Vd for the treatment of relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Bortezomib maintenance was associated with lower rates of moderate-to-severe cGVHD in newly diagnosed multiple myeloma after allo-HSCT.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.

Zoldonrasib produced responses and no grade 4 or 5 TRAEs in previously treated KRAS G12D–mutated NSCLC.

Daniel Johnson, MD, discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer.

Roswell Park Comprehensive Cancer Center launched a trial of a new CAR T-cell therapy for AML that has relapsed or persisted despite earlier treatment.

The FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC.

Sharon Castellino, MD, MSc, discusses the significance of the FDA approval of nivolumab plus AVD for stage III/IV classical Hodgkin lymphoma.

Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.